Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

Ventyx Biosciences announces positive topline Phase I data for its selective allosteric TYK2 inhibitor VTX958 Parker Aerospace and DUST Identity launch Lockheed Martin F-35 into digital space Ventyx Biosciences announces positive topline Phase I data for its peripheral NLRP3 inhibitor VTX2735 Cambridge Epigenetix names Peter Fromen as Chief Executive Officer Phase Four and Impulse Space to collaborate on multi-mode propulsion Vascular Therapies completes $25 million private financing
Back To News
Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial
May 11, 2021

Vascular Therapies announces clinical results from its Phase 3 randomized multicenter clinical trial

Vascular Therapies, a privately held biotechnology company is developing Sirogen, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels. Today the company announced clinical results from its Phase 3 clinical trial in which Sirogen showed encouraging AV fistula outcomes in elderly end-stage renal disease patients.

 

Cookie Policy Privacy Policy